Click here to receive MS news via e-mail
Tanuja Chitnis, MD, on how the PARADIGMS trial will test the best DMD for pediatric MS patients
I'm here to present to you today the PARADIGMS baseline characteristics. This is a randomized, double-blind study of fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis